Back to top
more

Dentsply Sirona (XRAY)

(Delayed Data from NSDQ)

$23.49 USD

23.49
2,328,568

+0.32 (1.38%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $23.47 -0.02 (-0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Medtronic's (MDT) EV ICD Pilot Study Results Encourage

The study highlights the benefits of traditional, transvenous ICDs offered by the Medtronic's (MDT) EV ICD system.

Nevro (NVRO) Q1 Loss Wider Than Expected, Revenues Down Y/Y

Nevro's (NVRO) domestic and international revenues fall year over year in Q1.

Here's Why You Should Invest in Illumina (ILMN) Stock Now

Illumina (ILMN) has been gaining investor confidence on robust performance.

National Vision's (EYE) Q1 Earnings Beat, Margins Decline

National Vision's (EYE) consistent strength in comps is owing to higher customer transaction for the past 69 straight quarters.

Syneos' (SYNH) Q1 Earnings Miss Estimates, Revenues In Line

Syneos Health (SYNH) sees strong year-over-year revenue growth across both operating segments ??? Clinical Solutions and Commercial Solutions.

LHC Group (LHCG) Earnings Beat, Revenues Miss Estimates in Q1

LHC Group (LHCG) gains from solid home health services in Q1, raises 2019 view.

BioScrip's Option Care Merger on Track, Q1 Loss Narrows

BioScrip (BIOS) is highly upbeat about the strategic and financial virtues of Option Care consolidation.

Cardinal Health (CAH) Q3 Earnings Top Estimates, Revenues Lag

Cardinal Health (CAH) Q3 results benefit from strong performance by Pharmaceutical segment and higher revenues. However, sluggishness in the Medical segment remains a concern.

Bio-Rad (BIO) Q1 Earnings Beat Estimates, Margins Expand

Bio-Rad (BIO) witnesses revenue growth at the Life Sciences segment in Q1 on strength in cell biology, droplet Digital PCR and other product lines.

Wright Medical (WMGI) Q1 Earnings & Revenues Top Estimates

Wright Medical (WMGI) Q1 results benefit from higher revenues, solid show by Lower as well as Upper Extremities segments and gross margin expansion. However, rising costs remain a woe.

OPKO Health (OPK) Reports Loss in Q1, Misses Revenue Estimates

Lower revenues, weak performing product segment and contraction in gross margin impact OPKO Health's (OPK) Q1 results.

Becton, Dickinson (BDX) Q2 Earnings Beat, Revenues Fall Y/Y

Becton, Dickinson (BDX) gains from BD Medical in fiscal Q2; international revenues down.

Phibro's (PAHC) Q3 Earnings Miss Estimates, Margins Fall

Phibro Animal Health (PAHC) sees year-over-year revenue decline in two core segments ??? Animal Health and Mineral Nutrition.

McKesson (MCK) Q4 Earnings Beat, Revenues Miss Estimates

McKesson's (MCK) Q4 results benefit from higher revenues, gross margin expansion and solid show by U.S. Pharmaceutical and Specialty Solutions.

Avanos (AVNS) Q1 Earnings Miss Estimates, Revenues Beat

Avanos (AVNS) Q1 results benefit from higher revenues, strong segmental performance and expansion in margins.

Allscripts (MDRX) Q1 Earnings Beat Estimates, Revenues Miss

Allscripts (MDRX) Q1 results gain from growth in bookings and solid show by client services segment. Contraction in margins remains a woe.

Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Up

Genomic Health (GHDX) registers strong year-over-year growth in revenues on solid domestic and overseas performances.

Inogen (INGN) Earnings Miss Estimates in Q1, View Lowered

Inogen (INGN) slashes revenue and net income guidance for 2019.

DaVita (DVA) Earnings and Revenues Miss Estimates in Q1

DaVita (DVA) gains from international revenues in Q1.

Myriad Genetics (MYGN) Q3 Earnings Top Estimates, Revenues Up

Myriad Genetics (MYGN) observes strong year-over-year revenue growth in EndoPredict, Hereditary Cancer and Prolaris testing as well as pharmaceutical and clinical service segments.

DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Top Estimates

DENTSPLY SIRONA (XRAY) Q1 earnings gain from Technology & Equipment unit despite international revenues being down.

Dentsply International (XRAY) Q1 Earnings and Revenues Top Estimates

Dentsply (XRAY) delivered earnings and revenue surprises of 28.95% and 3.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

DENTSPLY SIRONA (XRAY) Q1 Earnings: What's in the Cards?

Higher Consumable revenues, product innovation and focus on R&D likely to aid DENTSPLY SIRONA (XRAY) in Q1 earnings. However, contraction is gross margin might be a dampener.

Analysts Estimate Dentsply International (XRAY) to Report a Decline in Earnings: What to Look Out for

Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CONMED (CNMD) Beats on Q1 Earnings, Raises '19 Guidance

Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q1 earnings. However, high long-term debt remains a concern.